146 related articles for article (PubMed ID: 28371614)
1. Hypermutations in gliomas: a potential immunotherapy target.
Finocchiaro G; Langella T; Corbetta C; Pellegatta S
Discov Med; 2017 Feb; 23(125):113-120. PubMed ID: 28371614
[TBL] [Abstract][Full Text] [Related]
2. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
3. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.
Ezaki T; Sasaki H; Hirose Y; Miwa T; Yoshida K; Kawase T
Mol Med Rep; 2011; 4(6):1101-5. PubMed ID: 21874248
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients.
Crisafulli G; Sartore-Bianchi A; Lazzari L; Pietrantonio F; Amatu A; Macagno M; Barault L; Cassingena A; Bartolini A; Luraghi P; Mauri G; Battuello P; Personeni N; Zampino MG; Pessei V; Vitiello PP; Tosi F; Idotta L; Morano F; Valtorta E; Bonoldi E; Germano G; Di Nicolantonio F; Marsoni S; Siena S; Bardelli A
Cancer Discov; 2022 Jul; 12(7):1656-1675. PubMed ID: 35522273
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
[TBL] [Abstract][Full Text] [Related]
6. Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
Caporaso P; Turriziani M; Venditti A; Marchesi F; Buccisano F; Tirindelli MC; Alvino E; Garbin A; Tortorelli G; Toppo L; Bonmassar E; D'Atri S; Amadori S
DNA Repair (Amst); 2007 Aug; 6(8):1179-86. PubMed ID: 17500047
[TBL] [Abstract][Full Text] [Related]
7. MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Everhard S; Kaloshi G; Crinière E; Benouaich-Amiel A; Lejeune J; Marie Y; Sanson M; Kujas M; Mokhtari K; Hoang-Xuan K; Delattre JY; Thillet J
Ann Neurol; 2006 Dec; 60(6):740-3. PubMed ID: 17192931
[TBL] [Abstract][Full Text] [Related]
8. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy.
Hunter C; Smith R; Cahill DP; Stephens P; Stevens C; Teague J; Greenman C; Edkins S; Bignell G; Davies H; O'Meara S; Parker A; Avis T; Barthorpe S; Brackenbury L; Buck G; Butler A; Clements J; Cole J; Dicks E; Forbes S; Gorton M; Gray K; Halliday K; Harrison R; Hills K; Hinton J; Jenkinson A; Jones D; Kosmidou V; Laman R; Lugg R; Menzies A; Perry J; Petty R; Raine K; Richardson D; Shepherd R; Small A; Solomon H; Tofts C; Varian J; West S; Widaa S; Yates A; Easton DF; Riggins G; Roy JE; Levine KK; Mueller W; Batchelor TT; Louis DN; Stratton MR; Futreal PA; Wooster R
Cancer Res; 2006 Apr; 66(8):3987-91. PubMed ID: 16618716
[TBL] [Abstract][Full Text] [Related]
9. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
[TBL] [Abstract][Full Text] [Related]
11. Low c-Met expression levels are prognostic for and predict the benefits of temozolomide chemotherapy in malignant gliomas.
Li MY; Yang P; Liu YW; Zhang CB; Wang KY; Wang YY; Yao K; Zhang W; Qiu XG; Li WB; Peng XX; Wang YZ; Jiang T
Sci Rep; 2016 Feb; 6():21141. PubMed ID: 26879272
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
14. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
Fukushima T; Takeshima H; Kataoka H
Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
[TBL] [Abstract][Full Text] [Related]
15. An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.
Kyritsis AP; Levin VA
Cancer Chemother Pharmacol; 2011 May; 67(5):971-83. PubMed ID: 21442438
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in patients with high grade gliomas.
Brandes AA; Pasetto LM; Vastola F; Monfardini S
Oncology; 2000 Sep; 59(3):181-6. PubMed ID: 11053983
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide: a milestone in neuro-oncology and beyond?
Mutter N; Stupp R
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1187-204. PubMed ID: 16925485
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
[TBL] [Abstract][Full Text] [Related]
19. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
[TBL] [Abstract][Full Text] [Related]
20. [MGMT analysis in gliomas].
Quillien V; Vauléon E; Saikali S; Lesimple T; Hamlat A; Etcheverry A; Mosser J
Bull Cancer; 2011 Mar; 98(3):291-303. PubMed ID: 21459716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
